There are currently 580 clinical trials in Denver, Colorado looking for participants to engage in research studies. Trials are conducted at various facilities, including Porter Adventist Hospital, National Jewish Health, Rose Medical Center and Colorado Blood Cancer Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)
NCT04009681
Recruiting
Primary Objectives: Evaluate the safety and tolerability of THOR-707 as a single agent and as a combination therapy (identify Dose Limiting Toxcitiy (DLTs) in Cohorts A, B, C, D, and G, and adverse events (AEs)/serious adverse event (SAE) profile in Cohorts A, B, C, D, E, F, and G) Define the Maximium Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D) of THOR-707 as a single agent and as a combination therapy (Cohorts A, B, C, D, and G) Evaluate preliminary anti-tumor activity of T... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/04/2024
Locations: Investigational Site Number-1005, Denver, Colorado
Conditions: Metastasis
Register for Updates
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
NCT06026410
Recruiting
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyl transferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/04/2024
Locations: Sarah Cannon Research Institute at HealthONE, Denver, Colorado
Conditions: Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Clear Cell Renal Cell Carcinoma (ccRCC)
Register for Updates
Study of PYX-106 in Solid Tumors
NCT05718557
Recruiting
The primary objective of this study is to determine the recommended dose(s) of PYX-106 in participants with relapsed/refractory solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/04/2024
Locations: SCRI- HealthOne Denver, Denver, Colorado
Conditions: Solid Tumor
Register for Updates
Neuroblastoma Maintenance Therapy Trial
NCT02679144
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
Gender:
All
Ages:
Between 1 year and 30 years
Trial Updated:
04/04/2024
Locations: Rocky Mountain Pediatric Hematology, Denver, Colorado
Conditions: Neuroblastoma
Register for Updates
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
NCT05780034
Recruiting
This clinical trial is evaluating a drug called AC676 in participants with Relapsed/Refractory B-cell Malignancies. The main goals of the study are to: Identify the recommended dose of AC676 that can be given safely to participants Evaluate the safety profile of AC676 Evaluate the pharmacokinetics of AC676 Evaluate the effectiveness of AC676
Gender:
All
Ages:
18 years and above
Trial Updated:
04/03/2024
Locations: Colorado Blood Cancer Institute, Denver, Colorado
Conditions: Relapsed/Refractory B-cell Malignancies
Register for Updates
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT03723928
Recruiting
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/03/2024
Locations: Cancer Center of Colorado at Sloan's Lake, Denver, Colorado +11 locations
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
Register for Updates
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
NCT05806515
Recruiting
This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping, or slowing the growth of tumor cells. Giving carboplatin before surgery may shrink tumors in patients with h... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
04/03/2024
Locations: Porter Adventist Hospital, Denver, Colorado
Conditions: Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Register for Updates
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
NCT04657068
Recruiting
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan Learn more about the side effects of ART0380 alone and in combination with gemcitabine or irinotecan Learn more about the effectiveness of ART0380 alone and in combination with gemcitabine or irinotecan
Gender:
All
Ages:
18 years and above
Trial Updated:
04/02/2024
Locations: Sarah Cannon Research Institute at HealthONE, Denver, Colorado
Conditions: Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Register for Updates
The Crnic Institute Human Trisome Project Biobank
NCT02864108
Recruiting
The Human Trisome Project will significantly increase the speed of Down syndrome research and the understanding of associated medical conditions. Its biobank will provide de-identified samples to research.
Gender:
All
Ages:
Between 6 months and 89 years
Trial Updated:
04/01/2024
Locations: Linda Crnic Institute for Down Syndrome at the University of Colorado Denver, Denver, Colorado
Conditions: Down Syndrome, Trisomy 21
Register for Updates
Quality of Life and Life Satisfaction in Pediatric and Adolescent Gymnasts Through Injury
NCT05110729
Recruiting
This study aims to assess the quality and life and life satisfaction of pediatric and adolescent gymnasts throughout their musculoskeletal injury recovery.
Gender:
All
Ages:
Between 8 years and 18 years
Trial Updated:
04/01/2024
Locations: Children's Hospital Colorado, Denver, Colorado
Conditions: Musculoskeletal Injury, Quality of Life
Register for Updates
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
NCT04666688
Recruiting
A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with Metastatic Solid Tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: University of Colorado Hospital, Denver, Colorado +1 locations
Conditions: Metastatic Cancer, Solid Tumor, Colorectal Cancer, Pancreatic Cancer, Urothelial Carcinoma, Head and Neck Cancer
Register for Updates
To Compare the Efficacy and Safety of the HAV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis
NCT05908084
Recruiting
The goal of this clinical trial is to compare the number of catheter-free days (CFD) and the rate and severity of any dialysis access-related infections between the HAV and AVF groups over 12 months in patients with end-stage renal disease (ESRD) needing hemodialysis (HD). Participants will be stratified by location of the vascular access (forearm versus upper arm) and by type of AVF creation procedure planned by the surgeon at randomization (1-stage AVF versus 2-stage AVF). The comparator is a... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: Ernest E. Moore Shock Trauma Center at Denver Health, Denver, Colorado
Conditions: End Stage Renal Disease (ESRD)
Register for Updates